Onxeo S.A. buy Mori8
Start price
06.02.20
/
50%
€0.56
Target price
09.03.20
-
Performance (%)
-25.94%
End price
09.03.20
€0.42
Summary
This prediction ended on 09.03.20 with a price of €0.42. The price of Onxeo S.A. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -25.94%. Mori8 has 50% into this predictionOnxeo is a cutting-edge biotechnology company that specializes in the research and development of novel drugs to treat patients with rare or resistant cancers. Headquartered in Paris, France, this innovative firm has established itself as a leader in the field by leveraging its advanced platform, known as DNA Therapeutics, in conjunction with a comprehensive portfolio of small molecules and orphan oncology assets. With a strong commitment to scientific excellence and a robust intellectual property strategy, Onxeo aims to improve patient outcomes by addressing critical unmet medical needs and creating value for stakeholders through strategic partnerships and licensing deals.
Performance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Onxeo S.A. | -1.877% | -1.877% | -61.409% | -83.688% |
| iShares Core DAX® | 1.804% | -0.748% | 13.168% | 16.408% |
| iShares Nasdaq 100 | -0.182% | -3.412% | 39.976% | 43.502% |
| iShares Nikkei 225® | 0.413% | -7.381% | 18.776% | 2.874% |
| iShares S&P 500 | 0.664% | -1.941% | 28.141% | 42.155% |
Comments by Mori8 for this prediction
In the thread Onxeo S.A. diskutieren
Buy Onxeo S.A.